RIPK1-IN-17

RIPK1-IN-17 is an orally active, selective RIPK1 inhibitor (Kd = 17 nM) and shows no significant inhibition to RIPK3. RIPK1-IN-17 specifically inhibits necroptosis rather than apoptosis by inhibiting RIPK1, RIPK3, and MLKL phosphorylation. RIPK1-IN-17 protects mice from hypothermia and death. RIPK1-IN-17 can be used for the study of necroptosis-related diseases such as inflammatory response syndrome (SIRS) [1].

Product Specifications

CAS Number

[3033385-59-7]

UNSPSC

12352005

Target

Mixed Lineage Kinase; Necroptosis; RIP kinase

Type

Reference compound

Related Pathways

Apoptosis; MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ripk1-in-17.html

Purity

98.38

Solubility

10 mM in DMSO

Smiles

O=C(CC1=CC=CC(OC(F)(F)F)=C1)NC2=C(C=CC(C3=CC=C4N=C(SC4=C3)NC(C5CC5)=O)=C2)F

Molecular Formula

C26H19F4N3O3S

Molecular Weight

529.51

References & Citations

[1]Fang JJ, et al. Insight from Linker Investigations: Discovery of a Novel Phenylbenzothiazole Necroptosis Inhibitor Targeting Receptor-Interacting Protein Kinase 1 (RIPK1) from a Phenoxybenzothiazole Compound with Dual RIPK1/3 Targeting Activity. J Med Chem. 2023 Nov 2.